U.S. Veterinary Oncology Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Animal Type (Canine, Feline, and Others), Test Type, Cancer Type, and End Use

Description

List of Tables

The U.S. Veterinary Oncology Diagnostics Market size is expected to reach USD 2,228.87 Million by 2034, according to a new study by Polaris Market Research. The report "U.S. Veterinary Oncology Diagnostics Market Size, Share, Trends, Industry Analysis Report: By Animal Type (Canine, Feline, and Others), Test Type, Cancer Type, and End Use - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The U.S. Veterinary Oncology Diagnostics Market is defined as the sector involved in providing the tools, technologies, and services utilized by veterinary professionals in the United States to detect, diagnose, and monitor cancer in animal patients. This encompasses a diverse array of diagnostic modalities, including imaging techniques such as radiography, ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). It also includes laboratory-based tests like hematology, clinical chemistry, cytology, histopathology, and advanced molecular diagnostics such as polymerase chain reaction (PCR), flow cytometry, immunohistochemistry, and increasingly, genomic sequencing and liquid biopsies. The insights derived from these diagnostic procedures are critical for determining the presence and extent of neoplastic disease, guiding treatment decisions, and assessing the response to therapeutic interventions in companion animals and other veterinary species within the U.S.

The U.S. Veterinary Oncology Diagnostics Market is experiencing consistent growth, driven by several key factors. The increasing prevalence of cancer in the aging pet population, coupled with the strong and growing human-animal bond, leads to a greater demand for advanced veterinary care, including sophisticated cancer diagnostics. Technological advancements in veterinary medicine are also playing a significant role, with innovations in imaging, laboratory testing, and molecular diagnostics offering more accurate and less invasive methods for cancer detection. Furthermore, the rising awareness among pet owners about the availability and importance of early cancer diagnosis, along with the increasing accessibility of specialized veterinary oncology services, contributes to the expanding market. The availability of pet insurance is also facilitating greater utilization of advanced diagnostic procedures, further fueling the market's expansion across the United States.

U.S. Veterinary Oncology Diagnostics Market Report Highlights:

By animal type, the canine segment currently holds the largest market share in the U.S. Veterinary Oncology Diagnostics Market, primarily due to the higher incidence of cancer in dogs and their larger population as companion animals across the United States. This substantial segment reflects the strong inclination of dog owners to pursue advanced diagnostics for their pets when faced with a cancer diagnosis.

By test type, the imaging segment currently accounts for the largest share of the U.S. Veterinary Oncology Diagnostics Market, driven by the widespread and crucial role of various imaging modalities like radiography, ultrasound, CT, and MRI in the initial detection and staging of a broad range of cancers in animal patients throughout the United States.

By cancer type, the lymphoma segment currently represents the largest share of the U.S. Veterinary Oncology Diagnostics Market. This is mainly due to the relatively high occurrence of lymphoma in both canine and feline populations within the United States, making it one of the most frequently diagnosed cancers in veterinary practice nationwide.

By end use, the reference laboratories segment currently holds the largest share of the U.S. Veterinary Oncology Diagnostics Market. This is because a significant volume of specialized and complex cancer diagnostic testing, particularly advanced molecular analyses and histopathology, is outsourced by veterinary hospitals and clinics across the United States to these specialized facilities.

The prominent entities actively operating within the U.S. Veterinary Oncology Diagnostics market include Antech Diagnostics, Inc. (Mars Inc.), CANCAN DIAGNOSTICS, Embark Veterinary, Inc; Gold Standard Diagnostics (Eurofins Technologies); IDEXX Laboratories, Inc.; Neogen Corporation; Oncotect; PetDx; VolitionRx Limited; and Zoetis.

Polaris Market Research has segmented the U.S. Veterinary Oncology Diagnostics Market report based on animal type, test type, cancer type, end use, and region:

By Animal Type Outlook (Revenue-USD Billion, 2020-2034)

Canine

Feline

Others

By Test Type Outlook (Revenue-USD Billion, 2020-2034)

Blood Tests

Biopsy

Genome testing

Endoscopy

Urinalysis

Imaging

By Cancer Type Outlook (Revenue-USD Billion, 2020-2034)

Lymphoma

Sarcomas

Mammary Gland Tumors

Skin Cancers

Others

By End Use Outlook (Revenue-USD Billion, 2020-2034)

Reference Laboratories

Veterinary hospitals & clinics

Product Code: PM5646

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. U.S. Veterinary Oncology Diagnostics Market Insights

4.1. U.S. Veterinary Oncology Diagnostics Market - Market Snapshot
4.2. U.S. Veterinary Oncology Diagnostics Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Pet Ownership and the Human-Animal Bond
  - 4.2.1.2. Advancements in Veterinary Diagnostic Technologies
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Limited Awareness and Willingness
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Veterinary Oncology Diagnostics Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. U.S. Veterinary Oncology Diagnostics Market, by Animal Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Veterinary Oncology Diagnostics Market, by Animal Type, 2020-2034 (USD Million)
5.3. Canine
- 5.3.1. U.S. Veterinary Oncology Diagnostics Market, by Canine, by Region, 2020-2034 (USD Million)
5.4. Feline
- 5.4.1. U.S. Veterinary Oncology Diagnostics Market, by Feline, by Region, 2020-2034 (USD Million)
5.5. Others
- 5.5.1. U.S. Veterinary Oncology Diagnostics Market, by Others, by Region, 2020-2034 (USD Million)

6. U.S. Veterinary Oncology Diagnostics Market, by Test Type

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Veterinary Oncology Diagnostics Market, by Test Type, 2020-2034 (USD Million)
6.3. Blood Tests
- 6.3.1. U.S. Veterinary Oncology Diagnostics Market, by Blood Tests, by Region, 2020-2034 (USD Million)
6.4. Biopsy
- 6.4.1. U.S. Veterinary Oncology Diagnostics Market, by Biopsy, by Region, 2020-2034 (USD Million)
6.5. Genome testing
- 6.5.1. U.S. Veterinary Oncology Diagnostics Market, by Genome testing, by Region, 2020-2034 (USD Million)
6.6. Endoscopy
- 6.6.1. U.S. Veterinary Oncology Diagnostics Market, by Endoscopy, by Region, 2020-2034 (USD Million)
6.7. Urinalysis
- 6.7.1. U.S. Veterinary Oncology Diagnostics Market, by Urinalysis, by Region, 2020-2034 (USD Million)
6.8. Imaging
- 6.8.1. U.S. Veterinary Oncology Diagnostics Market, by Imaging, by Region, 2020-2034 (USD Million)

7. U.S. Veterinary Oncology Diagnostics Market, by Cancer Type

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Veterinary Oncology Diagnostics Market, by Cancer Type, 2020-2034 (USD Million)
7.3. Lymphoma
- 7.3.1. U.S. Veterinary Oncology Diagnostics Market, by Lymphoma, by Region, 2020-2034 (USD Million)
7.4. Sarcomas
- 7.4.1. U.S. Veterinary Oncology Diagnostics Market, by Sarcomas, by Region, 2020-2034 (USD Million)
7.5. Mammary Gland Tumors
- 7.5.1. U.S. Veterinary Oncology Diagnostics Market, by Mammary Gland Tumors, by Region, 2020-2034 (USD Million)
7.6. Skin Cancers
- 7.6.1. U.S. Veterinary Oncology Diagnostics Market, by Skin Cancers, by Region, 2020-2034 (USD Million)
7.7. Others
- 7.7.1. U.S. Veterinary Oncology Diagnostics Market, by Others, by Region, 2020-2034 (USD Million)

8. U.S. Veterinary Oncology Diagnostics Market, by End Use

8.1. Key Findings
8.2. Introduction
- 8.2.1. U.S. Veterinary Oncology Diagnostics Market, by End Use, 2020-2034 (USD Million)
8.3. Reference Laboratories
- 8.3.1. U.S. Veterinary Oncology Diagnostics Market, by Reference Laboratories, by Region, 2020-2034 (USD Million)
8.4. Veterinary hospitals & clinics
- 8.4.1. U.S. Veterinary Oncology Diagnostics Market, by Veterinary hospitals & clinics, by Region, 2020-2034 (USD Million)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Antech Diagnostics, Inc. (Mars Inc.)
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. CANCAN DIAGNOSTICS
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Embark Veterinary, Inc
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Gold Standard Diagnostics (Eurofins Technologies)
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. IDEXX Laboratories, Inc.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Neogen Corporation
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Oncotect
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. PetDx
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. VolitionRx Limited
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Zoetis
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development